体质量标化的肌酐与胱抑素C比值对中老年人群心血管事件的预测作用:基于CHARLS队列的全国前瞻性研究
收稿日期: 2026-04-11
修回日期: 2026-06-18
录用日期: 2026-06-22
网络出版日期: 2026-08-13
基金资助
天津市卫生健康科研项目(TJWJ2023QN108);天津市医学重点学科建设资助项目(TJYXZDXK-3-003B)
Prognostic value of the weight-adjusted creatinine-to-cystatin C ratio for cardiovascular events in middle-aged and older adults: A nationwide prospective study based on the CHARLS cohort
Received date: 2026-04-11
Revised date: 2026-06-18
Accepted date: 2026-06-22
Online published: 2026-08-13
目的 探讨我国中老年人群体质量标化的肌酐与胱抑素C比值(weight adjusted creatinine-to-cystatin C ratio,WCCR)与心血管疾病(cardiovascular disease,CVD)风险关联及预测价值。 方法 采用中国健康与养老追踪调查数据,选取参加2011年基线调查并追踪至2020年随访结束的5 994例中老年人为研究对象,收集其社会人口学特征、体格检查数据、生活方式信息、健康状况、医疗保险及生化指标等。采用血肌酐及胱抑素C指标计算体质量标化的WCCR,并按性别进行三份位数分组。采用Cox比例风险回归模型分析WCCR与CVD发病风险关联。 结果 中位随访8.92(7.00,9.00)年,共有1 517例发生CVD,其中心脏病1 158例,脑卒中521例。总体CVD、心脏病及脑卒中的发病密度分别为33.3/1 000人年(95%CI:31.7 ~ 35.0/1 000人年)、25.4/1 000人年(95% CI:24.0 ~ 26.9/1 000人年)和11.4/1 000人年(95%CI:10.5 ~ 12.5/1 000人年)。经多因素校正后,与WCCR最低分位数组相比,最高分位数组总体CVD和心脏病风险分别降低19.8%(95%CI:9.2% ~ 29.1%)和22.1%(95%CI:10.3% ~ 32.3%);在男性和女性的最高分位数组中总体CVD和心脏病风险分别降低19.5%(95%CI:2.6% ~ 33.5%)、20.9%(95%CI:0.6% ~ 37.1%)和20.3%(95%CI:6.3% ~ 32.3%)、25.0%(95%CI:9.7% ~ 37.8%)。 结论 在我国中老年人群中,WCCR与CVD风险呈负相关,较低的WCCR水平是心血管疾病的独立危险因素,该指标有助于完善心血管风险分层及防控策略。
张云盛 , 王娟 , 薛丽晶 , 贾莉莉 , 张文娟 . 体质量标化的肌酐与胱抑素C比值对中老年人群心血管事件的预测作用:基于CHARLS队列的全国前瞻性研究[J]. 实用医学杂志, 2026 , 42(15) : 2706 -2713 . DOI: 10.3969/j.issn.1006-5725.2026.15.005
Objective To investigate the association between the weight-adjusted creatinine-to-cystatin C ratio (WCCR) and the risk of incident cardiovascular disease (CVD) among middle-aged and older adults in China. Methods Data were obtained from the China Health and Retirement Longitudinal Study (CHARLS). A total of 5 994 participants who completed the 2011 baseline survey and were followed up until 2020 were included. Data on sociodemographic characteristics, physical examinations, lifestyle factors, health status, health insurance, and biochemical indicators were collected. The WCCR was calculated using serum creatinine and cystatin C levels, adjusted for body weight, and participants were categorized into sex-specific tertiles. Cox proportional hazards regression models were used to evaluate the association between the WCCR and the risk of CVD. Results Over a median follow-up of 8.92 (7.00, 9.00) years, 1 517 cases of CVD were recorded, including 1 158 cases of heart disease and 521 cases of stroke. The incidence densities of overall CVD, heart disease, and stroke were 33.3/1 000 person-years (95%CI: 31.7 - 35.0), 25.4/1 000 person-years (95%CI: 24.0 - 26.9), and 11.4/1 000 person-years (95%CI: 10.5 - 12.5), respectively. After multivariable adjustment, compared with the lowest WCCR tertile, the highest tertile was associated with a 19.8% (95%CI: 9.2% - 29.1%) reduction in overall CVD risk and a 22.1% (95%CI: 10.3% - 32.3%) reduction in heart disease. In the highest WCCR tertile, overall CVD risk was reduced by 19.5% (95%CI: 2.6% - 33.5%) in men and 20.3% (95%CI: 6.3% - 32.3%) in women, while heart disease risk was reduced by 20.9% (95%CI: 0.6% - 37.1%) in men and 25.0% (95%CI: 9.7% - 37.8%) in women. Conclusions Among middle-aged and older adults in China, the WCCR is inversely associated with the risk of CVD. A lower WCCR is an independent risk factor for cardiovascular events, highlighting its potential utility in improving cardiovascular risk stratification and informing prevention strategies.
| [1] | Global Burden Of Cardiovascular Diseases And Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023[J]. J Am Coll Cardiol, 2025, 86(22): 2167-2243. doi: 10.1016/j.jacc.2025.08.015 . |
| [2] | 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2024》要点解读[J].实用医学杂志,2025,41(14):2111-2131.doi:10.3969/j.issn.1006-5725.2025.14.001 . |
| [3] | 黄挺, 谢榕城, 王雨婷, 等. 肾阻力指数联合血液和尿液生物标志物早期预测介入术后造影剂诱导的急性肾损伤的价值[J]. 实用医学杂志, 2024, 40(7): 1011-1016. doi:10.3969/j.issn.1006-5725.2024.07.023 . |
| [4] | 吴澄, 金泓毅, 钟小梅. 动态监测血清脑钠肽、尿肾损伤分子-1、血清胱抑素C水平对小儿心脏术后急性肾损伤的评估价值[J]. 实用医学杂志, 2025, 41(13): 1964-1970. doi:10.3969/j.issn.1006-5725.2025.13.004 . |
| [5] | KARGER A B, SHLIPAK M G. Glomerular filtration rate (GFR) estimation with cystatin C—Past, present, and future[J]. Clin Chem, 2025, 71(7): 743-751. doi:10.1093/clinchem/hvae226 . |
| [6] | TABARA Y, KOHARA K, OKADA Y, et al. Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass in older adults: J-SHIPP study[J]. Clin Nutr, 2020, 39(6): 1857-1862. doi:10.1016/j.clnu.2019.07.027 . |
| [7] | KHALIL M, DI CIAULA A, JABER N, et al. Multidimensional assessment of sarcopenia and sarcopenic obesity in geriatric patients: Creatinine/cystatin C ratio performs better than sarcopenia index[J]. Metabolites, 2024, 14(6): 306. doi:10.3390/metabo 14060306 . |
| [8] | HIRAI K, TANAKA A, HOMMA T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J]. Clin Nutr, 2021, 40(3): 1274-1280. doi:10.1016/j.clnu.2020.08.010 . |
| [9] | WEI W, LI S, LIU J, et al. Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: A cohort study[J]. Diabetol Metab Syndr, 2022, 14(1): 176. doi:10.1186/s13098-022-00958-y . |
| [10] | HAN Y, ZHANG J, LI Q, et al. Association of serum creatinine/cystatin C ratio with insulin resistance and all-cause mortality: A national cohort analysis[J]. Front Nutr, 2025, 12: 1619618. doi:10.3389/fnut.2025.1619618 . |
| [11] | LIAO L, SHI S, DING B, et al. The relationship between serum creatinine/cystatin C ratio and mortality in hypertensive patients[J]. Nutr Metab Cardiovasc Dis, 2024, 34(2): 369-376. doi:10.1016/j.numecd.2023.09.004 . |
| [12] | CAI X, HU J, WANG M, et al. Association between the sarcopenia index and the risk of stroke in elderly patients with hypertension: A cohort study[J]. Aging (Albany NY), 2023, 15(6): 2005-2032. doi:10.18632/aging.204587 . |
| [13] | KHANG A R, LEE M J, YI D, et al. The ratio of estimated glomerular filtration rate based on cystatin C and creatinine reflecting cardiovascular risk in diabetic patients[J]. Diabetes Metab J, 2023, 47(3): 415-425. doi:10.4093/dmj.2022.0177 . |
| [14] | CHEN J, YAN L, HU L, et al. Association between the serum creatinine to cystatin C ratio and cardiovascular disease in middle-aged and older adults in China: A nationwide cohort study[J]. J Am Heart Assoc, 2025, 14(9): e040050. doi:10.1161/jaha.124.040050 . |
| [15] | 李淑萍, 张洁, 苑秋辰, 等. 心血管疾病患者肌少症指数与肌肉力量的剂量反应关系[J]. 中华现代护理杂志, 2026, 32(7): 896-902. doi:10.3760/cma.j.cn115682-20251017-05494 . |
| [16] | 何向阳, 刘峥, 郭艳芳, 等. 基于GBTM的老年人群抑郁症状变化轨迹与心血管疾病发病风险的关系[J]. 中华健康管理学杂志, 2026, 20(4): 321-328. doi:10.3760/cma.j.cn115624-20260112-00032 . |
| [17] | SUN H, WU Z, WANG G, et al. Normalized creatinine-to-cystatin C ratio and risk of cardiometabolic multimorbidity in middle-aged and older adults: Insights from the China health and retirement longitudinal study[J]. Diabetes Metab J, 2025, 49(3): 448-461. doi:10.4093/dmj.2024.0100 . |
| [18] | CHEN D, LI Y, RAN T, et al. Normalized creatinine-to-cystatin C ratio and cardiovascular disease risk in populations with cardiovascular-kidney-metabolic syndrome stages 0-3: Findings from a national and prospective cohort study[J]. Eur J Med Res, 2026, 31(1): 302. doi:10.1186/s40001-026-03905-z . |
| [19] | LIU X, ZHAN H, OU Y, et al. Normalized creatinine-to-cystatin C ratio and atherosclerotic cardiovascular disease risk in the UK Biobank[J]. Eur J Prev Cardiol, 2026: zwag113. doi:10.1093/eurjpc/zwag113 . |
| [20] | NISHIDA K, HASHIMOTO Y, KAJI A, et al. Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index[J]. Endocr J, 2020, 67(7): 733-740. doi:10.1507/endocrj.ej19-0542 . |
| [21] | DAMLUJI A A, ALFARAIDHY M, ALHAJRI N, et al. Sarcopenia and cardiovascular diseases[J]. Circulation, 2023, 147(20): 1534-1553. doi:10.1161/circulationaha.123.064071 . |
| [22] | BING S, CHEN Z, WU D, et al. Evolution of sarcopenia status and risk of incident cardiovascular disease[J]. Eur J Prev Cardiol, 2025: zwaf115. doi:10.1093/eurjpc/zwaf115 . |
| [23] | KALYANI R R, CORRIERE M, FERRUCCI L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases[J]. Lancet Diabetes Endocrinol, 2014, 2(10): 819-829. doi:10.1016/S2213-8587(14)70034-8 . |
| [24] | SAJEDIZADEH M, BAZMI S, DAVOUDI S H, et al. Insulin resistance and sarcopenia: Independent and combined associations with obesity and dietary protein intake[J]. J Endocrinol Investig, 2026. doi: 10.1007/s40618-026-02923-2 . |
| [25] | LI L, PAN Y, YAN H, et al. Predictive role of baseline serum creatinine-to-cystatin C ratio for renal dysfunction incidence in patients with acute ischemic stroke[J]. BMC Nephrol, 2026, 27(1): 172. doi:10.1186/s12882-026-04779-3 . |
| [26] | LIM Y J, SIDOR N A, TONIAL N C, et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: Mechanisms and therapeutic targets[J]. Toxins (Basel), 2021, 13(2): 142. doi:10.3390/toxins13020142 . |
/
| 〈 |
|
〉 |